Anthem Biosciences Ltd Q1 FY27 Results

Revenue -22.6% YoY; PAT -11.7% YoY; attributed to customer delivery timing shifts

PAT margin 27.1% (Q1 FY26 ~25.1%); EBITDA margin 39.6%. Both margins expanded YoY.

Unverified; consistent reiteration suggests credibility, but Q1 miss raises execution risk

Unit 2 utilization 50%, Unit 3 at 30-35%; dependent on customer order deferral assumptions

Raw material margin improvement, yield optimization, 13% employee cost (FY27 guidance); borne out

FY26 guidance: '20% or more growth' for FY27. Q1 FY27 delivered -22.6% YoY. Management claims 'growth is intact' for full year but won't quantify. This is a hedge, not a formal cut; guidance remains unquantified.

Supply chain pressures from war, raw material cost inflation noted. Specialty Ingredients revenue contribution softer than expected; expected to grow in H2 but at lower rate than CRDMO.

CDSCO approval timeline unchanged (expected Q3-Q4 FY27, 'quarter or two away'). No revenue in Q1; upside deferred.

Unit 1: 78% (vs 74% prior). Unit 2: 50% (vs 65%), expanded by 130 KL. Unit 3: 30-35% (ramp from 15%). FDA/EMA inspection timelines not discussed; focus on Unit 4 expansion.

One new Big Pharma onboarded (significant impact expected in later quarters). Large biotech acquired by Big Pharma. New peptide/oncology projects in Unit 3. Existing customers expanding volumes.

60% is whole business. CRDMO has order book concept (long lead manufacturing); specialty ingredients month-on-month. Remaining 40% from new customer onboarding, volume increases, and biotech project upside. Mix of both.

No commercial supply yet; awaiting CDSCO approval. Samples sent to major domestic players; they're waiting for approval. Scaling issues at peers noted but not primary driver. Timeline: approval expected this year.

60% order book locked in at known costs/margins for this year. Long-term: innovation (flow chemistry, bio-catalysis) drives customer value & cost reduction; new unit ramp will depress near-term PAT but margins defensible. Material margin already improving despite soft topline.

Not material for rest of year. Acquisition teams typically leave existing contracts untouched 1-2 years. Late Phase 3 contract; if clinical data is strong, could lead to commercial supply 1-2 years out. Viewing as long-term 'shot on goal' opportunity.

Geographic market uptake varies (China vs. France stocking imbalances). Customers anticipate sales, stock ahead, then defer when uptake slower. Also: regulatory approval delays shift timelines. Confirmed orders remain; just timing of shipment changes.

Phase 1: ₹1,200 Cr total capex (50-50 split FY27/FY28). Broke ground last year. By end FY28: 365 KL custom synthesis + 100 KL fermentation + food/nutra plant. Civil near done; equipment orders starting now.

Long-term historical growth is double-digit. FY27 growth is 'intact' and 'in line with historical performance.' Business is lumpy; Q1 soft, Q2-Q4 recovery. Look at YoY, not QoQ. No specific FY27 number given.

100+ early-stage, 10 late-phase (18-24 months to commercialization). Couple of ADC molecules in late phase. Peptide mostly early. Customers commercialized 4 new molecules last year; expect some of these 10 to commercialize soon.

Evolving landscape. Use cases: document review automation, chemistry prediction models. If AI generates more drug targets, Anthem benefits (more work for manufacturing/discovery). Already doing manufacturing automation; exploring further optimization. Early stage; clients themselves vague on AI adoption.

Promise-keeping, innovation (helping create new IP, not just 'pair of hands'), regulatory compliance track record, quality of manufacturing, quality of people (scientists interact directly). As units scale, innovation moat is hardest to preserve; must stay ahead through new modalities.

No explicit FY27 revenue target given. Contingent on 60% order book realization and Q2-Q4 recovery from Q1 deferral. Analyst challenged (Sheth, Khut); management refused to quantify.

Q1 tax rate low (16%) due to Neo Anthem (Unit 3) losses in prior year. Expected to break-even FY27. Material margin improving; cost discipline ongoing (13% employee cost, 9-10% other expenses FY27).

Unit 4: ₹1,200 Cr Phase 1 (50-50 split FY27/FY28). Civil nearing completion; equipment orders starting. By end FY28: 365 KL custom synthesis + 100 KL fermentation + food/nutra plant commissioned.

Management claims 60% order book visibility and customer deferrals explain Q1 miss. If order book is overstated or deferrals don't materialize, FY27 guidance ('growth intact') fails.

Semaglutide API awaiting CDSCO approval (expected Q3-Q4 FY27, 'quarter or two away'). Sampled to all major domestic players but no supply revenue yet. If approval delayed to FY28, upside shifts out.

81.5% of revenue from CRDMO; breakdown by customer not provided. Acquisition activity (biotech acquired by Big Pharma) suggests key customer dependency. Large customer deferrals drove Q1 miss; future deferrals could recur.

Unit 4 Phase 1 will add 365 KL custom synthesis + 100 KL fermentation by end FY28. Broke ground last year. Civil nearing completion; equipment orders just starting. Delays could compress profitability as capex drags yet capacity benefit is deferred.

Specialty Ingredients (18.5% of revenue) saw softness from supply chain pressures & raw material inflation (war-driven). Expected to recover in H2, but if inflation/disruption persists, margin could compress.